Germ-line alterations of BRCA1 are responsible for about 50% of familial breast cancers. Although its biological function (s) has not yet been fully determined, it has been suggested that it may act as a tumor suppressor gene in breast and ovarian cancers. In sporadic breast cancers alterations of BRCA1 have not been detected and in vitro experiments have indicated that BRCA1 negatively regulates cellular proliferation. The present study was designed to identify and quantify, the BRCA1 mRNA levels, in normal and neoplasic human breast tissue. BRCA1 mRNA molecules were quanti®ed using competitive reverse transcriptase PCR assays. DNA methylation patterns of this gene have been analysed by Southern blot experiments using methylation sensitive restriction enzymes. We found that BRCA1 mRNA levels were signi®cantly lower in sporadic breast cancers (37 cases analysed, 24 cases of invasive ductal carcinomas not otherwise speci®ed (NOS), two lobular carcinomas in situ two medullary carcinomas, four invasive lobular carcinomas, two invasive mucinous carcinomas and three invasive ductal carcinomas with predominantly in situ component) compared with normal breast tissues (P=0.0003). This down-regulation of BRCA1 is observed in all histologic types analysed. In invasive ductal carcinomas NOS, this down-regulation does not correlate with any of the prognostic factors studied (tumor size, node status, histologic grade, hormone receptor status). In the samples analysed, alterations of DNA methylation patterns were not dectected in the vicinity of the major transcription start site. These data suggest the involvement of BRCA1 in the carcinogenesis of these histologic types.
Introduction
Germ-line alterations of the BRCA1 gene have been shown to be responsible for about 50% of familial breast cancer (Friedman et al., 1994; Easton, 1997) . Although its biological function is still unknown, it has been suggested that BRCA1 may act as a tumor suppressor gene (Smith et al., 1992) . Indeed, as expected for a tumor suppressor gene, loss of the wild type allele is observed in more than 90% of the tumors carrying germ-line alterations of BRCA1 (Easton et al., 1997) . In addition, recent ®ndings demonstrating an association between BRCA1 and Rad 51 proteins suggest a role for this protein in DNA repair (Scully et al., 1997a) . However, the presence of a transactivation domain in BRCA1 and its stable association with RNA Polymerase II holenzyme (Scully et al., 1997b) indicate that BRCA1 might also be involved in the regulation of transcription. These two hypotheses, which are not mutually exclusive, stress that BRCA1 may have an important role in cellular dierentiation and proliferation. Direct evidence for an essential role of BRCA1 in mammalian development has been obtained from transgenic mice, since homozygous disruption of the BRCA1 gene results in embryonic lethality (Hakem et al., 1996) , and the progressive changes of BRCA1 expression during mouse embryogenesis also imply a role for BRCA1 in the dierentiation process (Marquis et al., 1995) . Alteration of the BRCA1 mRNA level has been observed in sporadic breast cancers, microdissections of biopsies from sporadic invasive breast tumors have shown a decrease in BRCA1 expression in the tumoral component of the samples (Thompson et al., 1995) . In addition, the involvement of BRCA1 in cellular proliferation has been also addressed in human cell lines, using antisense oligonucleotides (Thompson et al., 1995) and in mouse cell lines, using antisense RNAs (Rao et al., 1996) . All these experiments indicate that BRCA1 negatively regulates cellular proliferation.
Taken together these data suggest that alterations in BRCA1 mRNA levels might be a feature of human breast cancers. We have, therefore, investigated this hypothesis in human breast cancer biopsies. Tumors were assessed for histologic type, grade and prognostic factors and a total of 37 representative samples were analysed for their BRCA1 mRNA content using a quantitative RT-PCR method (Ribieras et al., 1997) .
Since somatic mutations of BRCA1 were not detected in human breast cancers Merajver et al., 1995) , alterations of DNA methylation patterns might be an alternative explanation for its down-regulation. It has been recently shown, by Southern blotting, that CpG sites around the exon 1a region were hypermethylated in some (two out seven) sporadic breast cancer cases (Dobrovic et al., 1997) . Alterations of DNA methylation patterns of BRCA1 gene have also been detected using the bisul®te genomic method (Mancini et al., 1998) . In two out of six breast cancers analysed, 21% and 16% of DNA molecules exhibit abnormal methylated CpGs at a cyclic AMP regulatory element binding protein (CREB) (position 7172 and 7167) in the vicinity of the major transcription start site .
In order to investigate the potential relationship between BRCA1 expression and DNA methylation, DNA methylation patterns in the 5' region and within the body of the gene were investigated by Southern blot experiments, after digestion with methylation sensitive restriction enzymes. Since ®rst reported (Frommer et al., 1992) , the bisul®te genomic sequencing method has been widely used for the analysis of DNA methylation patterns. This method is based on speci®c deamination of unmethylayed cytosines. After strand-speci®c ampli®cation of the deaminated DNA, the pattern of methylation is deduced from the sequence of PCR fragments. However, it has recently been shown that the quantitation of the relative amounts of methylated and unmethylated DNA at particular loci might be altered by PCR bias, depending on the sequence and/or the strand analysed (Warnecke et al., 1997) . Although the Southern blot method is less sensitive than bisul®te genomic sequencing and does not provide information about the CpGs outside restriction sites, this method does provide an evaluation of the methylation pro®les of all the DNA molecules from a given sample. Therefore, the methylation status of HpaII sites, including one at a CREB site (position 7167), was determined in normal and pathological breast tissues and compared with the steady-state BRCA1 mRNA level in these samples.
Results
Low abundance of BRCA1 mRNA in human sporadic breast cancer
The steady state level of BRCA1 mRNA was investigated in normal and pathological breast tissues using a competitive RT ± PCR method (Ribieras et al., 1997) . Germ-line alterations of BRCA1 are more frequently localized in the 3' one-third of the gene (Gayther et al., 1995) and only one case of alteration at the exons 6 and 8 has been reported (The Breast Cancer Information Core). Therefore, in order to amplify BRCA1 transcripts in a large panel of samples, primers were chosen in these two dierent exons together with a chimeric RNA derived from the same sequence but containing an insert of 48 bp, which was used as a competitor (Ribieras et al., 1997) . Some representative assays are shown in Figure 1 . Data obtained are summarized in Figure 2 and indicate that the BRCA1 mRNA level is signi®cantly decreased (P=0.0003) in tumoral tissue compared with normal breast tissues (37.054+42.4 and 179.2+40.8610 3 copies/mg of total RNA, respectively).
The samples analysed correspond to various histologic types (Table 1 ). However, this low level of Figure 1 RT ± PCR assay of BRCA1 mRNA in breast tissues. Fifteen ml of the RT ± PCR reaction mixture (total volume 100 ml) performed from serial dilutions of chimeric BRCA1 RNA and 0.6 mg of sample total RNA were analysed on ethidium bromide 2% agarose gel. The 306 bp band corresponds to the chimeric BRCA1 RNA. The 258 bp band corresponds to the wild type BRCA1 mRNA. The intensity of the bands were plotted against the initial number of standard molecules added. The RT ± PCR reactions were performed with 0.6 mg of total RNA from (a) normal breast tissue and (b, c, d) neoplasic breast samples BRCA1 mRNA does not seem to be associated with a speci®c histologic type of cancer (Table 1) . In invasive breast ductal carcinomas not otherwise speci®ed (NOS) a 5 ± 6-fold decrease in BRCA1 expression is observed (33.3+40.1610 3 copies/mg RNA, P=0.0004) compared with normal breast tissue. However, this low level of expression is also found in the other histologic types analysed, lobular carcinomas in situ, medullary carcinomas, invasive lobular carcinomas, invasive mucinous carcinomas and invasive ductal carcinomas with predominantly in situ component (Table 1 ).
The abundance of BRCA1 mRNA is not associated with a speci®c prognostic factor in invasive breast ductal carcinomas NOS
The biological and clinical characteristics of the invasive breast ductal carcinoma NOS samples analysed and their BRCA1 mRNA content are reported in Table 2 . From these data there is no meaningful association between BRCA1 expression and any other prognostic factor. However, although not statistically signi®cant, estrogen receptor rich (ER+) invasive breast carcinomas NOS exhibit a higher level of BRCA1 mRNA than that observed in the estrogen receptor negative samples (ER7). In line with this observation, in vitro studies indicate a potential relationship between estrogen receptors and the control of BRCA1 expression (Gudas et al., 1995; Xu et al., 1997) .
DNA methylation patterns of BRCA1 in normal and pathological breast tissues
Site-directed deletion mutagenesis of the 5' region of the BRCA1 gene lead to the identi®cation of a bidirectional promoter, position 7258 to +43 from the major transcription initiation start site (nt+1 of exon 1a) in the human mammary gland . This region contains several putative regulatory elements, Sp1 sites are present at positions 7163 and 7233 from exon 1a and a CREB site at position 7176 (Smith et al., 1996) .
Consequently, we ®rst analysed this 5' region of BRCA1, using a cloned DNA fragment (probe 1, Figure 3 ), in 37 neoplasic breast cancers and in two normal breast tissues. Probe 1 spans the BRCA1 gene nucleotide 3294 to 3606 and contains the region corresponding to the exon 1a (Smith et al., 1996) and maps HpaII sites within the promoter region, at positions 7167 (CREB site), +133 and +488, (Figure 3 ).
Since the BRCA1 pseudogene is the result of the duplication of the BRCA1 region containing the exons 1a, 1b and 2, probe one also matches (90% similarity) the BRCA1 pseudogene from nucleotides 1683 ± 1937 (Barker et al., 1996) . After TaqI (Figure 4a, lane 1) . Addition of MspI generates two DNA fragments at 0.35 kb and 0.3 kb (Figure 4a, lane 2) , consistent with the presence of the CCGG sites in this region (Figure 3a and 3b) . The 0.3 kb band corresponds to the BRCA1 gene and the 0.35 kb band corresponds to two unresolved bands, one at 0.351 kb from BRCA1 (Figure 3a) and the other at 0.364 kb from the pseudogene (Figure 3b) . When DNAs were cleaved by HpaII, the methylation sensitive enzyme, the patterns obtained were identical to those observed with MspI (Figure 4a , lanes 3 ± 5 and 8 ± 14), indicating that the CCGG sites at positions 7167, +133 and +484 are unmethylated.
However, in two samples out the 37 neoplasic breast tissue samples analysed, a selective hypermethylation of the BRCA1 pseudogene was observed indicated by the partial cleavage of the 1.5 kb TaqI-band (Figure 4a,  lanes 6 and 7) .
In order to map the CCGG sites within the body of the gene, ®lters were also hybridized with several cloned cDNA fragments and the representative patterns obtained with the probe two, encompassing cDNA region corresponding to the 3' end of the exon 11 to the exon 24, are shown in Figure 4b . Hybridization with probe two reveals, after TaqI Figure 3 DNA methylation pattern of the 5' region of the BRCA1 gene and pseudogene. (a), DNA extracted from the HeLa cell line was digested with the restriction endonuclease TaqI (T) or by TaqI and MspI (M). DNA extracted from normal breast (NB) or breast adenocarcinomas were cleaved by TaqI and the methylation sensitive enzyme HpaII. Southern blot experiments were performed as described in the Materials and methods section. DNA methylation patterns shown are representative of those observed in the normal and tumoral tissues studied. Lane 1, the 2.7 kb band corresponds to the exon 1a region of the BRCA1 gene. The probe 1 also reveals a 1.5 kb band corresponding to the BRCA1 pseudogene. Lane 2: the probe 1 reveals two bands for the BRCA1 gene: 299 and 351 bp and only one band for the BRCA1 pseudogene (364 bp). The same pattern is observed (lane 3) for normal breast tissue, (lanes 4 ± 7) for ER 7 breast adenocarcinomas and (lanes 8 ± 14) for ER + breast adenocarcinomas. The two ER 7 samples, exhibiting an hypermethylation of the 5' region of the BRCA1 pseudogene, are shown (lanes 6 and 7). (b) Partial restriction map of the 5' region of the BRCA1 gene and (c) pseudogene. The position of the dierent exons (exon 1a, exon 1b and exon 2) is indicated by black boxes and TaqI restriction sites by T. The probe used is a 350 bp fragment corresponding to the exon 1a region of the BRCA1 gene. The size of the fragments revealed by probe 1, after TaqI or TaqI-HpaII digestion, are indicated in bp. In the Southern blot experiments the 174 bp fragment was not detected using probe 1 BRCA1 mRNA in sporadic breast cancer F Magdinier et al digestion, several bands corresponding to dierent regions of the gene (Figure 4b , lane 1). Since the intronic regions contain several CCGG sites (Smith et al., 1996) , MspI digestion produces several novel bands. The dierent regions were identi®ed using several probes corresponding to the dierent exons present in this region ( Figure 4b , lane 2). HpaII patterns are similar to TaqI patterns, indicating that the CCGG sites are equally methylated in the normal and pathological samples analysed ( Figure  4b, lanes 3 to 12) . Taken together these data indicate that the DNA methylation pattern of BRCA1 is not altered in the breast cancer samples analysed and, as described for BRCA2 (Collins et al., 1997) , the putative promoter region of BRCA1 is unmethylated at CCGG sites.
Discussion
Using a quantitative RT ± PCR method (Ribieras et al., 1997) we have shown that BRCA1 transcripts can be quantitated in normal and pathological breast tissues. Our data provide evidence that the majority (33 out of 37) of the tumor samples analysed exhibit a 10 ± 12-fold decrease in BRCA1 mRNA, compared to that observed in normal breast tissue. In addition, the number of BRCA1 mRNA copies/mg of total RNA, in 12 out of BRCA1 mRNA in sporadic breast cancer F Magdinier et al 37 samples is 12 ± 22-fold lower than in normal breast tissue. These results, therefore, suggest that the downregulation of BRCA1 is a feature of sporadic breast cancers, since alteration of the BRCA1 mRNA level is observed in all histologic types of tumors analysed. However, two samples (an invasive ductal carcinoma NOS and a medullary carcinoma) exhibit a BRCA1 mRNA content similar to that found in normal tissue. These data may suggest that the down-regulation of BRCA1 is not a necessary event in the carcinogenic process or, alternatively, that the absence of any change in the BRCA1 mRNA level in cancer cells can be compensated for by other genic alterations, since it has been shown that breast cancer may have a multifactorial origin. In line with this hypothesis, the interaction of BRCA1 protein with Rad51 protein, the human homologue of the procaryotic RecA protein, suggests a role of BRCA1 in the double-stranded DNA repair mechanism. In addition, alterations in the BRCA1 mRNA level are not restricted to invasive breast carcinomas, similar alterations having been observed in all the histologic types of tumors analysed, including the two samples of lobular carcinomas in situ. Furthermore, in the ®broadenoma samples analysed, the BRCA1 mRNA level (134.7+10.44610 3 copies/mg of total RNA, n=4) was simililar to that found in normal breast tissue. Although the detection of BRCA1 proteins was not systematically performed, Westerns blot experiments have indicated, in cell lines, that the level of BRCA1 mRNA is correlated with the amount of BRCA1 proteins (data not shown).
Several lines of evidence indicate that BRCA1 negatively regulates cellular proliferation and may act as a suppressor gene in breast cancers. However, alterations in BRCA1 were not detected in sporadic breast cancer and were only exceptionally found in ovarian cancers Merajver et al., 1995) , suggesting that other mechanism(s) might be involved in its down-regulation in sporadic cancers.
Alteration of DNA methylation patterns is a very common event in cancer cells (Laird and Jaenisch; Counts and Goodman, 1995) and it has been shown that hypermethylation is associated with the down-regulation of several suppressor genes in human cancers (Gra et al., 1995; Huynh et al., 1996; Baylin et al., 1998) . In addition, the CCGG and GCGC sites located around the exon 1a of BRCA1 were found to be hypermethylated in some breast cancers samples (Dobrovic et al., 1997) and abnormal CpG methylations were detected in a small percentage (16% and 21% at CpG sites 7172 and 7167) of DNA molecules from two out six breast cancer samples analysed using the bisul®te genomic sequencing method (Mancini et al., 1998) .
In our work we found, in the majority of tumor samples (33 out of 37), a 10 ± 12-fold decrease in BRCA1 mRNA level. Furthermore, in 12 of these samples the number of BRCA1 mRNA molecules/mg of total RNA was 12 ± 22-fold lower than in normal breast tissue. Since the amount of BRCA1 mRNA is relatively low in normal breast tissue, ranging from six to 38 copies in breast cell lines (Ribieras et al., 1997) , these data indicate that the BRCA1 mRNA level is dramatically reduced in the majority of cancer cells within the samples analysed.
Southern blot experiments, performed with a DNA methylation sensitive enzyme from the same samples, show that the methylation pattern at the CCGG sites of the BRCA1 gene is not altered in sporadic breast cancers. Despite the fact that the sensitivity of this method does not allow for the detection of small percentage of abnormal methylation, these results indicate that the down-regulation of BRCA1 in sporadic breast cancer may not be associated with DNA hypermethylation or, alternatively, that DNA methylation might be involved in other regulatory regions not yet characterized.
Materials and methods

Sample preparation
For both normal and pathological samples, specimens were ®xed in formalin, paran embedded, sectioned and stained with hemaluneosin-safran. Breast tumors were classi®ed according to the WHO classi®cation of breast tumors (Poulsen et al., 1975) . After examination of the sections (Department of Pathology, Dr L Frappart), the region corresponding to the tumoral tissue was selected for further analysis. Neoplasic lesions comprised invasive ductal carcinomas NOS (n=24), lobular carcinomas in situ (n=2), medullary carcinomas (n=2), invasive lobular carcinomas (n=4), invasive mucinous carcinomas (n=2) and invasive ductal carcinomas with predominantly in situ component (n=3). Normal breast tissues were obtained from patients (n=6) undergoing mammoplastic surgery.
DNA/RNA extraction DNA was extracted from frozen tissues by standard procedures (Sambrook et al., 1989) . RNA was extracted using the RNAzol method (Bioprobe, Paris, France), a modi®cation of the guanidium procedure . After isopropanol precipitation, the pellet was washed in 708C ethanol and dissolved in an appropriate volume of sterile water. The integrity and quantity of RNA was then examined by gel electrophoresis. Total RNA was quanti®ed by densitometry on agarose gel in comparison with serial dilutions of known amounts of standard RNA (Boehringer Mannheim, Meylan, France).
RT ± PCR assay
RT ± PCR assay was performed as previously described (Ribieras et al., 1997) . Brie¯y, 0.6 mg of total RNA was coampli®ed with dierent amounts of chimeric BRCA1 RNA as a competitor in a ®nal volume of 100 ml containing 10 mM Tris-HCl, 3 mM MgCl 2 , 50 mM KCl, 0.1 mg/ml Gelatin, 200 mM each of the four deoxyribonucleoside triphosphates and 0.25 mM of each of the C3 primer; 5' TGT GCT TTT CAG CTT GAC ACA GG 3', position 390 ± 412; 5' CGT CTT TTG AGG TTG TAT CCG CTG 3', position 624 ± 647 (Friedman et al., 1994) . After initial denaturation at 948C for 2 min, 17.5 units of Expand Reverse Transcriptase (Boehringer Mannheim, Meylan, France) were added to the reaction mixture and incubated for 35 min at 428C. Reverse Transcriptase was inactivated by heating for 2 min at 948C and then, cooling to 08C. PCR ampli®cation of the cDNA was accomplished by adding 0.6 units of TaqI DNA polymerase (Boehringer Mannheim, Meylan, France). The PCR ampli®cation was performed after 35 cycles in a thermocycler under the following conditions: 1 min denaturation at 948C, 2 min annealing at 658C and 3 min extension at 728C. In addition, control experiments for each RNA sample were performed omitting reverse transcriptase to ensure that the BRCA1 mRNA in sporadic breast cancer F Magdinier et al signal was the result of RNA and not DNA ampli®cation. PCR products were analysed on a 2% agarose gel containing 0.1 mg/ml ethidium bromide. The gels were photographed under ultraviolet transillumination, the photographs were scanned and the intensity of the PCRband corresponding to wild-type BRCA1 mRNA was plotted against the intensity of the PCR product corresponding to the competitor.
Southern blot analysis of DNA methylation patterns
Methylation patterns were determined by Southern blot experiments using the pair of isoschizomeric restriction endonucleases, HpaII and MspI. MspI yielded fragments resulting from the cleavage of all CCGG sites, whereas HpaII only cleaved CCGG with unmethylated internal cytosine. In order to map these sites, all DNAs were also cleaved with TaqI, a methylation insensitive endonuclease.
To control the eciency of HpaII digestion, several samples were digested once or twice, with a tenfold excess of this enzyme. Southern blot experiments have shown that the pattern of HpaII digested DNAs was not modi®ed in the double digested samples.
Restriction endonuclease digests were fractionated on a 1.2% agarose electrophoresis gel and then transferred to Hybond N+ Nylon membrane as previously described . Membranes were hybridized for 16 h at 428C to randomly primed 32 P-labeled probes (Random Primed DNA labeling kit, Boehringer Mannheim, Meylan, France) in a buer containing 50% Formamide, 10% Dextran Sulfate, 0.7 M NaCl, 1% SDS and 300 mg/ml denatured herring sperm DNA. Membranes were washed with increasing stringency (from 26to 0.26SSPE; 1% SDS) at 658C and exposed to Hyper®lm (Amersham, France) for 1 ± 7 days using an intensifying screen. Nylon membranes could be used for rehybridizations after two successive treatments with SDS 1% at 808C for 30 min. The same ®lters were successively hybridized to several probes.
Gene probes
The probes used for Southern blot analysis were synthesised by PCR or RT ± PCR (Friedman et al., 1994) . The PCR or RT ± PCR fragments were cloned into a pGEM-T vector (Promega, Lyon, France). Following digestion with the appropriate enzymes, the inserts were puri®ed by agarose gel electrophoresis followed by electroelution. Probes one and two fully matched the BRCA1 gene sequence (results not shown).
